Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759 on ClinicalTrials.gov · last registry update 2026-08-03
Closed to new participants; the 330 already enrolled are still being followed. Due to report 12 May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Relative change in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. cagrilintide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- cagrilintide
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 330
- Started
- 2025-11-05
- Primary completion
- 2027-05-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Relative change in body weight
Conditions studied
Overweight · Obesity · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the cagrilintide page for this molecule’s full trial and approval history.